In TNBC models, bispecific or dual-target CAR-T designs, such as those targeting B7-H3/CSPG4 or mesothelin/NKG2D ligands, have demonstrated potent cytotoxicity and superior tumor regression compared with single-target CAR-T approaches. Here, CD276 is linked to neoplasm.